{"id":"W4417011691","doi":"10.1182/blood-2025-910","title":"Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Discontinuation; Clinical endpoint; Adverse effect; Phases of clinical research; Myelofibrosis; Placebo; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003395528,0.001266975,0.001947526,0.0002861521,0.0004822941,0.001448417,0.0007183008,0.001324494,0.002890966],"category_scores_gemma":[0.001441861,0.0004749788,0.001991838,0.0003404542,0.0006010568,0.001178459,0.0004382396,0.003604639,0.001002519],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006221934,"about_ca_system_score_gemma":0.0006865051,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005935594,"about_ca_topic_score_gemma":0.001264792,"domain_scores_codex":[0.9993373,0.0003094682,0.0000563964,0.0001040846,0.00008653788,0.000106382],"domain_scores_gemma":[0.9984193,0.0002241123,0.0004781971,0.0002119719,0.0001260261,0.0005403328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7903599,0.0336248,0.01778129,0.001140505,0.004002735,0.0003924372,0.0002529641,0.00259308,0.04768071,0.0002113245,0.01059268,0.09136755],"study_design_scores_gemma":[0.5037896,0.3829873,0.0942783,0.0001247655,0.002882996,0.0007843884,0.0001453906,0.002164838,0.006876835,0.0003235906,0.005517901,0.0001240065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856831,0.005995342,0.0008496827,0.0005983126,0.0001480104,0.000737148,0.004197218,0.0001831349,0.001608017],"genre_scores_gemma":[0.9855561,0.002173146,0.0009281501,0.0008483412,0.0002413637,0.0007772428,0.006530713,0.00004267594,0.002902461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003395528,"threshold_uncertainty_score":0.01795751,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01738875086058434,"score_gpt":0.2848147305685922,"score_spread":0.2674259797080079,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}